866-997-4948(US-Canada Toll Free)

Chronic Back Pain Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Mar 2013

Category :

Oncology

No. of Pages : 55 Pages


Global Markets Directs, \'Chronic Back Pain Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Chronic Back Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Back Pain. 

Chronic Back Pain Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Chronic Back Pain.
  • A review of the Chronic Back Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Chronic Back Pain pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Chronic Back Pain.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Chronic Back Pain pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Chronic Back Pain Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Chronic Back Pain 7
Chronic Back Pain Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Chronic Back Pain Therapeutics Products under Development by Companies 14
Companies Involved in Chronic Back Pain Therapeutics Development 15
BioDelivery Sciences International, Inc. 15
Zogenix, Inc. 16
Teva Pharmaceutical Industries Limited 17
Collegium Pharmaceutical, Inc. 18
Mesoblast Ltd 19
Grunenthal GmbH 20
Sosei Co. Ltd. 21
Chronic Back Pain Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
hydrocodone bitartrate ER - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
buprenorphine hydrochloride - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
cebranopadol - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
hydrocodone bitartrate ER - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
SD-726 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
oxycodone ER - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Mesenchymal Precursor Cells For Chronic Back Pain - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
AYX-2 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
AKR-202 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
AKR-203 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Chronic Back Pain Therapeutics Drug Profile Updates 42
Chronic Back Pain Therapeutics Discontinued Products 51
Chronic Back Pain Product Development Milestones 52
Featured News & Press Releases 52
Oct 18, 2012: Collegium Pharma Announces Poster Presentation On Oxycodone DETERx At 2012 American Association Of Pharmaceutical Scientists Annual Meeting 52
Jul 06, 2012: Lilly Obtains Six Months US Pediatric Exclusivity For Cymbalta 52
Feb 03, 2010: Eli Lilly Reports Cymbalta Significantly Reduced Chronic Low Back Pain In A New Study 53

Appendix 54

Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 55
Disclaimer 55

List of Table


Number of Products Under Development for Chronic Back Pain, H1 2013 7
Products under Development for Chronic Back Pain Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Comparative Analysis by Late Stage Development, H1 2013 10
Comparative Analysis by Mid Clinical Stage Development, H1 2013 11
Comparative Analysis by Early Clinical Stage Development, H1 2013 12
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
BioDelivery Sciences International, Inc., H1 2013 15
Zogenix, Inc., H1 2013 16
Teva Pharmaceutical Industries Limited, H1 2013 17
Collegium Pharmaceutical, Inc., H1 2013 18
Mesoblast Ltd, H1 2013 19
Grunenthal GmbH, H1 2013 20
Sosei Co. Ltd., H1 2013 21
Assessment by Monotherapy Products, H1 2013 22
Assessment by Stage and Route of Administration, H1 2013 24
Assessment by Stage and Molecule Type, H1 2013 26
Chronic Back Pain Therapeutics Drug Profile Updates 42
Chronic Back Pain Therapeutics Discontinued Products 51

List of Chart


Number of Products under Development for Chronic Back Pain, H1 2013 7
Products under Development for Chronic Back Pain Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Late Stage Products, H1 2013 10
Mid Clinical Stage Products, H1 2013 11
Early Clinical Stage Products, H1 2013 12
Pre-Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 22
Assessment by Route of Administration, H1 2013 23
Assessment by Stage and Route of Administration, H1 2013 24
Assessment by Molecule Type, H1 2013 25
Assessment by Stage and Molecule Type, H1 2013 26

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *